Early initiation of eicosapentaenoic acid and statin treatment is associated with better clinical outcomes than statin alone in patients with acute coronary syndromes: 1-year outcomes of a randomized controlled study

التفاصيل البيبلوغرافية
العنوان: Early initiation of eicosapentaenoic acid and statin treatment is associated with better clinical outcomes than statin alone in patients with acute coronary syndromes: 1-year outcomes of a randomized controlled study
المؤلفون: Toru Miyoshi, Keisuke Okawa, Naoaki Matsuo, Kazumasa Nosaka, Saori Tsukuda, Masayuki Doi, Hiroshi Ito, Masahito Kajiya, Mutsumi Iwamoto, Tomoyuki Nishibe, Masahiro Sogo, Fumi Yokohama, Satoshi Hirohata
المصدر: International Journal of Cardiology. 228:173-179
بيانات النشر: Elsevier BV, 2017.
سنة النشر: 2017
مصطلحات موضوعية: Acute coronary syndrome, medicine.medical_specialty, Statin, medicine.drug_class, medicine.medical_treatment, 030204 cardiovascular system & hematology, Catheterization, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, medicine, Clinical endpoint, 030212 general & internal medicine, Myocardial infarction, Inflammation, business.industry, Percutaneous coronary intervention, Fatty acids, statins, medicine.disease, Cardiovascular diseases, Infarction, Conventional PCI, Cardiology, lipids (amino acids, peptides, and proteins), business, Cardiology and Cardiovascular Medicine, TIMI
الوصف: Background Early initiation of EPA treatment in combination with a statin within 24h after percutaneous coronary intervention (PCI) in patients with acute myocardial infarction (MI) reduces inflammation and ventricular arrhythmia compared with statin monotherapy; however, the impact of early initiation of EPA treatment on cardiovascular events is unclear. We determined whether early eicosapentaenoic acid (EPA) treatment in patients with acute coronary syndrome (ACS) reduces adverse cardiovascular events. Methods This prospective, open-label, blind end point–randomized trial consisted of 241 patients with ACS. Patients were randomly assigned to receive pitavastatin (2mg/day) with or without 1800mg/day of EPA initiated within 24h after PCI. The primary endpoint was defined as cardiovascular events occurring within 1year, including death from a cardiovascular cause, nonfatal stroke, nonfatal MI and revascularization. Results The mean EPA/arachidonic acid ratio at follow-up was 0.40 in the control group and 1.15 in the EPA group. A primary endpoint event occurred in 11 patients (9.2%) in the EPA group and 24 patients (20.2%) in the control group (absolute risk reduction, 11.0%; hazard ratio, 0.42; 95% confidence interval, 0.21 to 0.87; P=0.02). Notably, death from a cardiovascular cause at 1year was significantly lower in the EPA group than in the control group (0.8% vs. 4.2%, P=0.04). Conclusions Early initiation of treatment with EPA combined with statin after successful primary PCI reduced cardiovascular events after ACS. Clinical Trial Registration: UMIN Clinical Trials Registry (UMIN-CTR); Registry Number, UMIN000016723; URL, http://www.umin.ac.jp/ctr/index-j.htm
تدمد: 0167-5273
DOI: 10.1016/j.ijcard.2016.11.105
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bdcbccedc72173499a76f93a53454833
حقوق: OPEN
رقم الأكسشن: edsair.doi.dedup.....bdcbccedc72173499a76f93a53454833
قاعدة البيانات: OpenAIRE
الوصف
تدمد:01675273
DOI:10.1016/j.ijcard.2016.11.105